Veru's Phase 2b PLATEAU trial fully enrolled with 239 obesity patients

Veru Inc. said its Phase 2b PLATEAU clinical trial exceeded its targeted full enrollment of 200 patients by enrolling 239 patients during the quarter.¹ The trial is evaluating enobosarm in combination with a GLP-1 receptor agonist for higher quality weight reduction in older patients with obesity.¹

The company said results of an interim analysis assessing lean body mass and fat mass by DXA after patients complete 32 weeks are expected in the first quarter of calendar year 2027, with final topline data expected in the fourth quarter of calendar year 2027.¹

In June 2026, Veru said it entered into a clinical supply agreement with Novo Nordisk for the Phase 2b PLATEAU study.¹ In August 2026, the company said it received a USPTO Notice of Allowance for a patent application titled "Compositions Comprising Selective Androgen Receptor Modulator Compounds in Combination with Weight Loss Drugs and Uses Thereof for Quality Weight Loss," with the USPTO determining the application meets patentability requirements and is expected to issue as a U.S. patent.¹ Veru said that once issued, the patent will have an expiry of at least October 3, 2044, prior to any potential patent term adjustment or extension.¹

On earlier pipeline work, Veru said its completed Phase 2b QUALITY clinical study was a positive multicenter, double-blind, placebo-controlled, randomized, dose-finding trial evaluating enobosarm 3 mg, enobosarm 6 mg, or placebo in 168 older patients receiving semaglutide (Wegovy®) for weight reduction.¹

On finances, Veru reported cash, cash equivalents and restricted cash of $23.9 million as of June 30, 2026, up from $15.8 million as of September 30, 2025.¹ For the quarter, net loss decreased to $7.0 million, or $0.30 per share, compared to $7.3 million, or $0.50 per share, in the year-earlier period.¹